Enhanced oval bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833

British Journal of Cancer

Volumn 76, Issue 9, 1997, Pages 1181-1183

  Van Asperen, J ^a   Van Tellingen, O ^a   Sparreboom, A ^a,c   Schinkel, A H ^a   Borst, P ^a   Nooijen, W J ^a   Beijnen, J H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Oral bioavailability; P glycoprotein; Paclitaxel (Taxol); Reversal agent; SDZ PSC 833

Indexed keywords

ALCOHOL; CREMOPHOR; GLYCOPROTEIN P; PACLITAXEL; VALSPODAR; CYCLOSPORIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ANIMAL; BIOAVAILABILITY; BLOOD; DRUG ANTAGONISM; DRUG COMBINATION; MOUSE STRAIN; TIME;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINS; DRUG COMBINATIONS; FEMALE; MICE; MICE, INBRED STRAINS; P-GLYCOPROTEIN; PACLITAXEL; TIME FACTORS;

EID: 0030613634     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.530     Document Type: Article

References (18)

1. Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P and Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233
2. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P and Housman DE (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9: 1346-1350
3. Dorr RT (1994) Pharmacology and toxicology of cremophor EL diluent. Ann Pharmacother 28: s11-s14
4. Eiseman JL, Eddington ND, Leslie J, McAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D and Egorin MJ (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34: 465-471
5. Fisher GA, Lum BL, Hausdorff J and Sikic BI (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A: 1082-1088
6. Fujita H, Okamoto M, Takao A, Mase H and Kojima H (1994) Pharmacokinetics of paclitaxel in experimental animals. Part I. Blood level (Japanese). Kan to Kagaku Ryoho 21: 653-658
7. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026-4035
8. Huizing MT, Sewberath Misser VH, Pieters RC, Ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM and Beijnen JH (1995) Taxanes: a new class of antitumor agents. Cancer Invest 13: 381-404
9. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P and Hiestand PC (1992) SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50: 593-597
10. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer (see comment citations in Medline). N Engl J Med 334: 1-6
11. Rowinsky EK and Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332: 1004-1014
12. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502
13. Shet MS, Fisher CW, Holmans PL and Estabrook RW (1993) Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc Natl Acad Sci USA 90: 11748-11752
14. Sparreboom A, van Tellingen O, Nooijen WJ and Beijnen JH (1995) Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J Chromatogr 664: 383-391
15. Sparreboom A, van Tellingen O, Nooijen WJ and Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115
16. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH and van Tellingen O (1997) Limited oral bioavailability und active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035
17. Teeter LD, Becker FF, Chisari FV, Li DJ and Kuo MT (1990) Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 10: 5728-5735
18. Wacher VJ, Salphati L and Benet LZ (1996) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 20: 99-112